These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8421706)

  • 1. Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease.
    Wright CI; Guela C; Mesulam MM
    Proc Natl Acad Sci U S A; 1993 Jan; 90(2):683-6. PubMed ID: 8421706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease.
    Wright CI; Geula C; Mesulam MM
    Ann N Y Acad Sci; 1993 Sep; 695():65-8. PubMed ID: 8239315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
    Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
    Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.
    Wright CI; Geula C; Mesulam MM
    Ann Neurol; 1993 Sep; 34(3):373-84. PubMed ID: 8363355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
    Mesulam MM; Geula C; Morán MA
    Ann Neurol; 1987 Dec; 22(6):683-91. PubMed ID: 3435078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinesterases and the pathology of Alzheimer disease.
    Geula C; Mesulam MM
    Alzheimer Dis Assoc Disord; 1995; 9 Suppl 2():23-8. PubMed ID: 8534419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinesterase activity in the plaques, tangles and angiopathy of Alzheimer's disease does not emanate from amyloid.
    Geula C; Greenberg BD; Mesulam MM
    Brain Res; 1994 May; 644(2):327-30. PubMed ID: 8050043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease.
    Geula C; Mesulam M
    Brain Res; 1989 Sep; 498(1):185-9. PubMed ID: 2790472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and histochemical comparison of cholinesterases in normal and Alzheimer brain tissues.
    Darvesh S; Reid GA; Martin E
    Curr Alzheimer Res; 2010 Aug; 7(5):386-400. PubMed ID: 19939227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical differentiation of cholinesterases from normal and Alzheimer's disease cortex.
    Ciro A; Park J; Burkhard G; Yan N; Geula C
    Curr Alzheimer Res; 2012 Jan; 9(1):138-43. PubMed ID: 21244353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Preliminary Evaluation of Phenyl 4-123I-Iodophenylcarbamate for Visualization of Cholinesterases Associated with Alzheimer Disease Pathology.
    Macdonald IR; Reid GA; Pottie IR; Martin E; Darvesh S
    J Nucl Med; 2016 Feb; 57(2):297-302. PubMed ID: 26541777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competitive substrate inhibition in the histochemistry of cholinesterase activity in Alzheimer's disease.
    Schätz CR; Geula C; Mesulam M
    Neurosci Lett; 1990 Sep; 117(1-2):56-61. PubMed ID: 2290622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterases in the amyloid angiopathy of Alzheimer's disease.
    Mesulam M; Carson K; Price B; Geula C
    Ann Neurol; 1992 May; 31(5):565-9. PubMed ID: 1375822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylcholinesterase and its association with heparan sulphate proteoglycans in cortical amyloid deposits of Alzheimer's disease.
    Kalaria RN; Kroon SN; Grahovac I; Perry G
    Neuroscience; 1992 Nov; 51(1):177-84. PubMed ID: 1465181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease.
    Mesulam MM; Asuncion Morán M
    Ann Neurol; 1987 Aug; 22(2):223-8. PubMed ID: 3662453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterase histochemistry in the human brain: effect of various fixation and storage conditions.
    Morán MA; Gómez-Ramos P
    J Neurosci Methods; 1992 Jun; 43(1):49-54. PubMed ID: 1528073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brains of aged and Alzheimer's disease patients.
    Gómez-Ramos P; Bouras C; Morán MA
    Brain Res; 1994 Mar; 640(1-2):17-24. PubMed ID: 8004445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A gorge-spanning, high-affinity cholinesterase inhibitor to explore beta-amyloid plaques.
    Elsinghorst PW; Härtig W; Goldhammer S; Grosche J; Gütschow M
    Org Biomol Chem; 2009 Oct; 7(19):3940-6. PubMed ID: 19763296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase.
    Nachon F; Carletti E; Ronco C; Trovaslet M; Nicolet Y; Jean L; Renard PY
    Biochem J; 2013 Aug; 453(3):393-9. PubMed ID: 23679855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.